PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Kroidl, I.* ; Winter, S.* ; Rubio-Acero, R.* ; Bakuli, A.* ; Geldmacher, C.* ; Eser, T.M.* ; Deák, F.* ; Horn, S.* ; Zielke, A.* ; Ahmed, M.I.M.* ; Diepers, P.* ; Guggenbühl, J.* ; Frese, J.* ; Bruger, J.* ; Puchinger, K.* ; Reich, J.* ; Falk, P.* ; Markgraf, A.* ; Fensterseifer, H.* ; Paunovic, I.* ; Thomschke, A.* ; Pritsch, M.* ; Riess, F.* ; Saathoff, E.* ; Hoelscher, M.* ; Olbrich, L.* ; Castelletti, N. ; Wieser, A.*

Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison.

Virol. J. 20:200 (2023)
Publ. Version/Full Text DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Background: Measuring specific anti-SARS-CoV-2 antibodies has become one of the main epidemiological tools to survey the ongoing SARS-CoV-2 pandemic, but also vaccination response. The WHO made available a set of well-characterized samples derived from recovered individuals to allow normalization between different quantitative anti-Spike assays to defined Binding Antibody Units (BAU). Methods: To assess sero-responses longitudinally, a cohort of ninety-nine SARS-CoV-2 RT-PCR positive subjects was followed up together with forty-five vaccinees without previous infection but with two vaccinations. Sero-responses were evaluated using a total of six different assays: four measuring anti-Spike proteins (converted to BAU), one measuring anti-Nucleocapsid proteins and one SARS-CoV-2 surrogate virus neutralization. Both cohorts were evaluated using the Euroimmun Anti-SARS-CoV-2-ELISA anti-S1 IgG and the Roche Elecsys Anti-SARS-CoV-2 anti-S1 assay. Results: In SARS-CoV-2-convalesce subjects, the BAU-sero-responses of Euroimmun Anti-SARS-CoV-2-ELISA anti-S1 IgG and Roche Elecsys Anti-SARS-CoV-2 anti-S1 peaked both at 47 (43–51) days, the first assay followed by a slow decay thereafter (> 208 days), while the second assay not presenting any decay within one year. Both assay values in BAUs are only equivalent a few months after infection, elsewhere correction factors up to 10 are necessary. In contrast, in infection-naive vaccinees the assays perform similarly. Conclusion: The results of our study suggest that the establishment of a protective correlate or vaccination booster recommendation based on different assays, although BAU-standardised, is still challenging. At the moment the characteristics of the available assays used are not related, and the BAU-standardisation is unable to correct for that.
Impact Factor
Scopus SNIP
Altmetric
4.800
0.000
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Keywords Antibody ; Binding Antibody Units ; Covid-19 ; Nucleocapsid ; Rbd ; Sars-cov-2 ; Serology ; Spike; Antibody-response; Surveillance; Bnt162b2
Language english
Publication Year 2023
HGF-reported in Year 2023
e-ISSN 1743-422x
Journal Virology Journal
Quellenangaben Volume: 20, Issue: 1, Pages: , Article Number: 200 Supplement: ,
Publisher BioMed Central
Publishing Place Campus, 4 Crinan St, London N1 9xw, England
Reviewing status Peer reviewed
Institute(s) Institute of Radiation Medicine (IRM)
POF-Topic(s) 30203 - Molecular Targets and Therapies
Research field(s) Radiation Sciences
PSP Element(s) G-501391-001
Grants KoCo19/ORCHESTRA Study group: Mohamed IbraheemMohamed Ahmed, Emad Alamoudi, Jared Anderson, Valeria Baldassarre, Abhishek Bakuli, Maximilian Baumann, Marc Becker, Franziska Bednarski, Marieke Behlen, Olimbek Bemirayev, Jessica Beyerl, Patrick
DOI 10.1186/s12985-023-02167-z
WOS ID 001062515700002
Scopus ID 85169681023
PubMed ID 37658454
Erfassungsdatum 2023-10-18
[➜Report correction]